Kamada Ltd. (KMDA)
NASDAQ: KMDA · Real-Time Price · USD
7.08
-0.03 (-0.42%)
Dec 5, 2025, 4:00 PM EST - Market closed
Kamada Revenue
Kamada had revenue of $47.01M in the quarter ending September 30, 2025, with 12.63% growth. This brings the company's revenue in the last twelve months to $130.08M, up 12.18% year-over-year. In the year 2024, Kamada had annual revenue of $160.95K, down -99.89%.
Revenue (ttm)
$130.08M
Revenue Growth
+12.18%
P/S Ratio
2.34
Revenue / Employee
$416,160
Employees
420
Market Cap
409.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160.95K | -142.36M | -99.89% |
| Dec 31, 2023 | 142.52M | 13.18M | 10.19% |
| Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
| Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
| Dec 31, 2020 | 133.25M | 6.06M | 4.76% |
| Dec 31, 2019 | 127.19M | 12.72M | 11.11% |
| Dec 31, 2018 | 114.47M | 11.64M | 11.32% |
| Dec 31, 2017 | 102.83M | 25.33M | 32.69% |
| Dec 31, 2016 | 77.49M | 7.59M | 10.85% |
| Dec 31, 2015 | 69.91M | -1.16M | -1.63% |
| Dec 31, 2014 | 71.07M | 442.00K | 0.63% |
| Dec 31, 2013 | 70.62M | -2.05M | -2.82% |
| Dec 31, 2012 | 72.68M | 13.19M | 22.18% |
| Dec 31, 2011 | 59.48M | 25.01M | 72.53% |
| Dec 31, 2010 | 34.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KMDA News
- 26 days ago - Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth - GlobeNewsWire
- 4 weeks ago - Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - GlobeNewsWire
- 2 months ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 months ago - Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety - Seeking Alpha
- 4 months ago - Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025 - GlobeNewsWire
- 6 months ago - Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East - GlobeNewsWire